There's no guarantee that a better competing offer isn't waiting in the wings either. Ocata's science and huge IP portfolio must have a lot of appeal in the science/pharma world. Sure is a ballgame and after all these years, a shame not to see it go it's full course.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.